(NASDAQ: ANNX) Annexon's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.27%.
Annexon's revenue in 2026 is $0.On average, 12 Wall Street analysts forecast ANNX's revenue for 2026 to be $13,840,319,095, with the lowest ANNX revenue forecast at $0, and the highest ANNX revenue forecast at $113,052,999,780. On average, 10 Wall Street analysts forecast ANNX's revenue for 2027 to be $7,696,815,711, with the lowest ANNX revenue forecast at $2,251,010,840, and the highest ANNX revenue forecast at $13,189,516,641.
In 2028, ANNX is forecast to generate $43,460,205,037 in revenue, with the lowest revenue forecast at $17,932,957,320 and the highest revenue forecast at $93,708,375,373.